help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geller, J.
Right arrow Articles by Loza, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geller, J.
Right arrow Articles by Loza, D.

Journal of Clinical Endocrinology & Metabolism, Vol 52, 576-580, Copyright © 1981 by Endocrine Society

ARTICLES

Medical castration of males with megestrol acetate and small doses of diethylstilbestrol

J Geller, J Albert, SS Yen, S Geller and D Loza

An alternative program for medical castration for treatment of prostate cancer has been developed using a progestational antiandrogen, megestrol acetate (MA), in combination with small doses of diethylstilbestrol (DES; 0.1 mg/day). The administration of MA (40-80 mg/day) with 0.1 mg DES to nine patients resulted in castrate levels of plasma testosterone (less than 0.4 ng/ml) and significant suppression of both FSH and LH (P less than 0.05) for up to 12 months. Although large clinical trials must ultimately establish its safety, clinical side effects of this combined therapy to date have consisted of mild gynecomastia in two patients. The symptoms did not necessitate discontinuing the medications. It is concluded that the use of 0.1 mg DES with a minimum of 40 mg/day MA results in medical castration with sustained suppression of plasma testosterone. Because of the possible additional therapeutic advantage of blockade of intracellular androgen- mediated action by MA in androgen-dependent tumors, this combined therapy should be further explored as a possible initial treatment of choice for advanced prostate cancer.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
C. P. Lambert, D. H. Sullivan, S. A. Freeling, D. M. Lindquist, and W. J. Evans
Effects of Testosterone Replacement and/or Resistance Exercise on the Composition of Megestrol Acetate Stimulated Weight Gain in Elderly Men: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2100 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. A. Eisenberger, B. A. Blumenstein, E. D. Crawford, G. Miller, D. G. McLeod, P. J. Loehrer, G. Wilding, K. Sears, D. J. Culkin, I. M. Thompson, et al.
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
N. Engl. J. Med., October 8, 1998; 339(15): 1036 - 1042.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1981 by The Endocrine Society